Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | CCR2 | P41597 | 1/20 | 0.66 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259323 | 1.00 | CXCR4 (0.67) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| Bromide SCHEMBL7495511 | 0.98 | CXCR4 (0.68) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| Bromide SCHEMBL1259133 | 0.96 | CXCR4 (0.66) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL17929341 | 0.96 | CXCR4 (0.72) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL674945 | 0.95 | CXCR4 (0.75) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| Bromide SCHEMBL5675524 | 0.92 | CXCR4 (0.71) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL6237364 | 0.88 | SIGMAR1 (0.61) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL674847 | 0.88 | CXCR4 (0.65) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL18548884 | 0.87 | CXCR4 (0.59) | CXCR4TDP1MEN1CHRM2CHRM1 | |
| SCHEMBL29823861 | 0.87 | CXCR4 (0.69) | CXCR4TDP1MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161859-A1 | USE OF CXCR4 ANTAGONISTS | University of Washington Center for Commercialization | 2021-06-03 | — | — | US | claimed |
| US-20150030561-A1 | Use of CXCR4 Antagonists | GENZYME CORP. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2709991-A1 | USE OF CXCR4 ANTAGONISTS | Genzyme Corporation (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012158707-A1 | USE OF CXCR4 ANTAGONISTS | GENZYME CORPORATION (US) | 2012-11-22 | — | — | WO | claimed |
| EP-2391211-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | Genzyme Corporation (US) | 2011-12-07 | — | — | EP | claimed |
| US-20110280827-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | HU YANPING (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281814-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION | 2011-11-17 | — | — | US | claimed |
| EP-2384115-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Genzyme Corporation (US) | 2011-11-09 | — | — | EP | claimed |
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| WO-2010088401-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088398-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2010-08-05 | — | — | WO | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| WO-2008109076-A1 | METHODS FOR ENHANCING THE EFFICACY OF VASCULAR DISRUPTING AGENTS | OXIGENE, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080214509-A1 | Methods for enhancing the efficacy of vascular disrupting agents | OXIGENE, INC. | 2008-09-04 | — | — | US | claimed |
| JP-3375961-B2 | — | — | 2003-02-10 | — | — | JP | claimed |
| EP-1223166-A1 | Linked cyclic polyamines with activity against hiv. | AnorMED Inc. (CA) | 2002-07-17 | — | — | EP | claimed |
| US-5583131-A | FOR TREATMENT OR PREVENTION OF ACQUIRED IMMUNE DEFICIENCY SYNDROME, REDUCED TOXICITY | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1996-12-10 | — | — | US | claimed |
| EP-0619813-A1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1994-10-19 | — | — | EP | claimed |
| WO-1993012096-A1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1993-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214509-A1 | Methods for enhancing the efficacy of vascular disrupting agents | CXCL12, CXCR4, CXCR2 | CXCR4 2/4885TDP1 2023/4885MEN1 2440/4885 |
| US-20210161859-A1 | USE OF CXCR4 ANTAGONISTS | CXCR4, CXCR2, CXCR3 | CXCR4 1/4885TDP1 3497/4885MEN1 3707/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | CXCR4 2/4885TDP1 4573/4885MEN1 4046/4885 |
| US-20150030561-A1 | Use of CXCR4 Antagonists | CXCR4, CXCR2, CXCR3 | CXCR4 1/4885TDP1 3497/4885MEN1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.